- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Review, Journal: Herpes zoster infection in patients with inflammatory bowel disease. (Pubmed Central) - May 14, 2025
Given the higher incidence of HZ in certain populations, such as those in Korea, vaccination recommendations should be adapted accordingly. Further research is needed to evaluate the long-term effectiveness of Shingrix in younger patients with IBD to ensure sustained protection and prevent complications, such as postherpetic neuralgia.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Review, Journal: Exploring the Potential Stimuli and Deterrents of Varicella-Zoster Viral Reactivation: A Scoping Review. (Pubmed Central) - May 1, 2025
Three articles with data regarding PHN pathophysiology suggested that it is more likely caused by neurological damage with some genetic influence rather than further viral reactivation. While further investigation into the relationship between viral reactivation and risk factors is warranted based on this analysis, the results suggest that immunosuppression that has been previously linked to or correlated with these variables likely also contributes to VZV reactivation and PHN.
- |||||||||| Zostavax (zoster vaccine live) / Merck (MSD)
Observational data, Journal: The relationship between Zoster serology, vaccination uptake and infection rates: a single-centre cross-sectional study. (Pubmed Central) - Oct 29, 2024
In total, 8.6% of the cohort received the Zostavax vaccine, despite a small yet significant number of patients (4.3%) experiencing Herpes Zoster after initiating treatment...Barriers to vaccination include inconsistent guidelines, limited vaccine availability and patient-level hesitancy. This is concerning as our cohort demonstrated small but significant rates of zoster, mostly among patients on long-term steroids.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Phase classification, Trial completion date: Persistence of Protection by Shingrix (clinicaltrials.gov) - Oct 15, 2024
P4, N=105, Completed,
This is concerning as our cohort demonstrated small but significant rates of zoster, mostly among patients on long-term steroids. Phase classification: P1 --> P4 | Trial completion date: Mar 2023 --> Jun 2024
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Journal: Assessing herpes zoster vaccine efficacy in patients with diabetes: A community-based cohort study. (Pubmed Central) - May 13, 2024
Subgroup analyses across age, sex, and follow-up duration also showed no significant differences. These findings underscore the lack of a significant benefit from HZ vaccination in newly diagnosed diabetes patients aged over 50, highlighting the necessity for further prospective research.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
P4 data, Journal: Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia. (Pubmed Central) - Apr 28, 2024
While rates of AEFIs was higher with HZ/su than ZVL, most AEFIs were mild and did not require medical attention. Our findings support the change in vaccine recommendations and the use of HZ/su in immunisation programs.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Review, Journal: Time to talk to adults with rheumatic diseases about herpes zoster vaccination. (Pubmed Central) - Feb 20, 2024
Moreover, a recombinant herpes zoster vaccine (Shingrix) has become available that can be given to these patients in a more accessible manner than the original live-attenuated vaccine (Zostavax). Here, we evaluate existing evidence on risk factors for herpes zoster and the safety and efficacy of the recombinant vaccine in patients with rheumatic immune-mediated inflammatory diseases and discuss the necessity of herpes zoster vaccination for these patients.
- |||||||||| Orencia (abatacept) / BMS, Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date: BMS-188667: The Immunogenicity and Safety of Zostavax (clinicaltrials.gov) - Feb 14, 2024
P2, N=154, Active, not recruiting,
Here, we evaluate existing evidence on risk factors for herpes zoster and the safety and efficacy of the recombinant vaccine in patients with rheumatic immune-mediated inflammatory diseases and discuss the necessity of herpes zoster vaccination for these patients. Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jun 2024 --> Jun 2025
- |||||||||| Orencia (abatacept) / BMS, Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Trial completion date, Trial primary completion date: BMS-188667: The Immunogenicity and Safety of Zostavax (clinicaltrials.gov) - Jan 17, 2024
P2, N=130, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jun 2024 --> Jun 2025 Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jul 2023 --> Jun 2024
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Preclinical, Journal: Immunogenicity in Mice Immunized with Recombinant Adenoviruses Expressing Varicella-Zoster Virus Envelope Glycoprotein E. (Pubmed Central) - Dec 27, 2023
The results showed similar CD4 T and CD8 T cell responses to Shingrix were induced in mice vaccinated using rChAd63/gE via different immune pathways. This study elucidates that recombinant adenoviruses expressing VZV gE could be appropriate for further development as a new HZ vaccine candidate via different immune pathways.
- |||||||||| Zostavax (zoster vaccine live) / Merck (MSD)
Trial completion, Trial primary completion date: Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients (clinicaltrials.gov) - Nov 22, 2023
P=N/A, N=68, Completed,
This study elucidates that recombinant adenoviruses expressing VZV gE could be appropriate for further development as a new HZ vaccine candidate via different immune pathways. Active, not recruiting --> Completed | Trial primary completion date: May 2023 --> Sep 2023
- |||||||||| Zostavax (zoster vaccine live) / Merck (MSD)
Journal: Shingles Vaccine Uptake Among Older Adults: Identifying Early, Later, and Nonadopters. (Pubmed Central) - Nov 5, 2023
This study examined factors that differentiate the acceptance and timing of uptake of the first shingles vaccine, Zostavax, among older adults in the U.S. Data from Health and Retirement Study respondents who were aged ?62 years in 2008 were analyzed to determine whether they received a shingles vaccination from 2006 to 2016...Shingles vaccination rates vary by social and geographic characteristics. Efforts to improve and expedite vaccination and other new preventive measures should target specific populations and geographic areas.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Journal: Surveying a Sample of the Spanish Ophthalmologic Community about Vaccination against Herpes Zoster. (Pubmed Central) - May 27, 2023
Considering the sequelae, complications, and the existence of safe and effective vaccines against HZ, vaccination of the target population could be considered an important public health measure. We are convinced that it is time for ophthalmologists to take an active role in HZO prevention.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Trial completion: Persistence of Protection by Shingrix (clinicaltrials.gov) - May 10, 2023
P1, N=105, Completed,
We are convinced that it is time for ophthalmologists to take an active role in HZO prevention. Recruiting --> Completed
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Review, Journal: Association of asthma and herpes zoster, the role of vaccination: A literature review. (Pubmed Central) - Nov 3, 2022
Shingrix is preferred by FDA which is a two doses vaccine that is given 6 months apart for people above 50 years and to immunocompromised people. Hence, proper counseling and education about the risks of herpes should be informed to the patients with timely utilization of the vaccine.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Observational data, Retrospective data, Journal: Adherence to Herpes Zoster (Shingles) Catch-Up Campaign at the Romagna Local Health Authority (Italy), a Multi-Center Retrospective Observational Study. (Pubmed Central) - Oct 28, 2022
In both centers, the need for greater synergy between public health departments and general practitioners to engage their patients emerged, as did the need for additional recall measures. Studying the main drivers of vaccine hesitancy, especially at the local level, can help in targeting campaigns and catch-up activities in order to achieve widespread acceptance.
- |||||||||| Zostavax (zoster vaccine live) / Merck (MSD)
Journal: Vaccination Reduces Risk of Alzheimer's Disease, Parkinson's Disease and Other Neurodegenerative Disorders. (Pubmed Central) - Oct 26, 2022
Shingles (HZV) vaccine Zostavax reduces risk of AD and PD...Once embryologic reactivation has occurred in the brain of an older person and AD or PD develops, this complex process relentlessly destroys the protective mechanism it created in utero. Unanswered question: Are the AD-risk-reducing effects of flu, pneumonia, and shingles vaccinations cumulative?
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Preclinical, Journal: LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix in VZV-primed mice. (Pubmed Central) - Oct 19, 2022
Number of IL-2 and IFN-γ secreting splenocytes and proportion of T helper 1 (Th1) cytokine-expressing CD4 T cells in LNP-CpG-adjuvanted VZV-gE vaccinated mice were similar to that of Shingrix boosted mice. All of the components in this LNP vaccine can be artificially and economically synthesized in large quantities, indicating the potential of LNP-CpG-adjuvanted VZV-gE as a more cost-effective zoster vaccine.
- |||||||||| Journal: Adult immunization. (Pubmed Central) - Oct 14, 2022
All of the components in this LNP vaccine can be artificially and economically synthesized in large quantities, indicating the potential of LNP-CpG-adjuvanted VZV-gE as a more cost-effective zoster vaccine. No abstract available
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Journal: Active Post-Licensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data. (Pubmed Central) - Oct 5, 2022
Recombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster and its complications in older adults...Among 647,833 RZV doses administered from January 2018 through December 2019, we did not detect a sustained increased risk of any monitored outcome for RZV recipients relative either to historical (2013-2017) recipients of Zoster Vaccine Live (ZVL), a live-attenuated virus vaccine (Zostavax; Merck & Co., Inc., Kenilworth, New Jersey), or contemporary non-RZV vaccinated persons who had an annual well-visit during the 2018-2019 study period...Our study provides additional reassurance about the overall safety of RZV. Despite a large sample, uncertainty remains regarding potential associations with GBS due to the limited number of confirmed GBS cases that were observed.
- |||||||||| Orencia (abatacept) / BMS, Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Trial primary completion date: BMS-188667: The Immunogenicity and Safety of Zostavax (clinicaltrials.gov) - Apr 20, 2022
P2, N=130, Recruiting,
Community pharmacy-based HZ vaccination was associated with lower cost and greater outcomes. Trial primary completion date: Dec 2023 --> Jul 2023
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Review, Journal, HEOR: Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. (Pubmed Central) - Mar 29, 2022
Even among countries with developed economies that license the vaccine, few have implemented HZ vaccination into their national immunization schedules due to cost-effectiveness considerations. In this review, we discuss the currently available HZ vaccines, landscape of HZ vaccine guidelines, and economic burden of disease in countries with developed and developing economies, as well as barriers and considerations in HZ vaccine access on a global scale.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
Review, Journal: Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide. (Pubmed Central) - Mar 17, 2022
This review will discuss risk for shingles in patients with inflammatory bowel diseases, available vaccines, and their efficacy and safety profiles. We will also provide guidance on who, when, and how to vaccinate for herpes zoster in routine clinical practice amongst patients with inflammatory bowel diseases.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Journal: Herpes Zoster Vaccines. (Pubmed Central) - Mar 11, 2022
Additional zoster vaccines are in different stages of development. Wider distribution of safe and effective zoster vaccines will improve the health and well being of the rapidly growing population of older adults around the world.
|
